IPP Bureau
ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia
By IPP Bureau - August 08, 2025
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
WACKER and Gearbox Biosciences collaborate to advance pDNA manufacturing technologies
By IPP Bureau - August 08, 2025
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
By IPP Bureau - August 08, 2025
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg
By IPP Bureau - August 07, 2025
This is the group’s first NoC approval in Canada
Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr
By IPP Bureau - August 06, 2025
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
By IPP Bureau - August 06, 2025
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
By IPP Bureau - August 06, 2025
Cenexi reports an EBITDA breakeven for the quarter
AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients
By IPP Bureau - August 06, 2025
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Athena Diagnostics enhances Ataxia testing with long-read gene sequencing
By IPP Bureau - August 06, 2025
Athena is also exploring the use of this technology for expanded carrier screening
AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata
By IPP Bureau - August 06, 2025
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines
By IPP Bureau - August 06, 2025
Vasograin Plus represents a major advancement in the treatment of migraine
Roche’s Susvimo maintains vision over five years
By IPP Bureau - August 06, 2025
Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs
By IPP Bureau - August 06, 2025
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure
By IPP Bureau - August 06, 2025
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Aster DM Healthcare to build Rs. 580 crore crore hospital in Bengaluru
By IPP Bureau - August 05, 2025
This will be Aster’s fifth hospital in Bengaluru
